Anavex, Glovia, And India Globalization Capital: The Future Of Alzheimer's Treatments [Seeking Alpha]
IGC Pharma, Inc. (IGC)
NASDAQ:AMEX Investor Relations:
igcinc.us/investor-center/overview
Company Research
Source: Seeking Alpha
Anavex, Glovia, And India Globalization Capital: The Future Of Alzheimer's Treatments Summary Anavex 2-73, Glovia's Feru-guard, and India Globalization Capital's Hyalolex act as antioxidants which is likely the key to treating Alzheimer's disease. Glovia is not currently a publicly traded company in the United States; regardless, its natural product holds considerable promise for the treatment of Alzheimer's disease. India Globalization Capital's management and products have come under sharp criticism. Results from Anavex's current Alzheimer's trial will not be available until March 2021. After each Alzheimer’s drug failure, the inevitable question is always asked what are we doing wrong. Anavex ( AVXL IGC Each company’s drug candidate acts as an antioxidant and this is likely the key to treating Alzheimer’s disease. Following is compelling evidence that oxidation and nitration are the key factors behind the onset and progression of Alzheimer’s disease: The increase in oxidative stres
Show less
Read more
Impact Snapshot
Event Time:
IGC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IGC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IGC alerts
High impacting IGC Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
IGC
News
- IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s PipelineAccesswire
- IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss TherapiesAccesswire
- IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1Accesswire
- IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE ChallengeAccesswire
- IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's TreatmentBusiness Wire
IGC
Analyst Actions
- 9/3/24 - Ascendiant Capital
IGC
Sec Filings
- 11/12/24 - Form 10-Q
- 9/27/24 - Form 8-K
- 9/27/24 - Form 4
- IGC's page on the SEC website